Long-term use of glimepiride may improve survival and reduce hospitalizations in hospitalized patients with concomitant type 2 diabetes and chronic HF, researchers reported.
In addition, high-dose daily glimepiride further reduced risk for CV mortality in this patient population compared with low-dose treatment, according to a prospective study published in the European Journal of Preventive Cardiology.
“Third-generation [sulfonylureas], such as glimepiride, are widely used for treating [type 2 diabetes] because of their definite hypoglycemic efficacy, relatively low risk of hypoglycemia,